key: cord-0691190-ne9hokqk authors: Wu, Jing; Shi, Yuheng; Pan, Xiaoyan; Wu, Shuang; Hou, Ruixia; Zhang, Yong; Zhong, Tiansheng; Tang, Hao; Du, Wei; Wang, Luying; Wo, Jing; Mu, Jingfang; Qiu, Yang; Yang, Ke; Zhang, Lei-Ke; Ye, Bang-Ce; Qi, Nan title: SARS-CoV-2 ORF9b Inhibits RIG-I-MAVS Antiviral Signaling by Interrupting K63-Linked Ubiquitination of NEMO date: 2021-02-03 journal: Cell Rep DOI: 10.1016/j.celrep.2021.108761 sha: 2c4d4ed84b9753cb01d7d0c100bcfba4f7350910 doc_id: 691190 cord_uid: ne9hokqk COVID-19 is a current global health threat caused by the novel coronavirus SARS-CoV-2. Emerging evidence indicates that SARS-CoV-2 elicits a dysregulated immune response and a delayed interferons (IFNs) expression in patients, which contribute largely to the viral pathogenesis and development of COVID-19. However, underlying mechanisms remain to be elucidated. Here, we report the activation and repression of innate immune response by SARS-CoV-2. We show that SARS-CoV-2 RNA activates the RIG-I-MAVS-dependent IFN signaling pathway. We further uncover that ORF9b immediately accumulates and antagonizes the antiviral type I IFN response during SARS-CoV-2 infection on primary human pulmonary alveolar epithelial cells. ORF9b targets the NF-κB essential modulator NEMO and interrupts its K63-linked polyubiquitination upon viral stimulation, thereby inhibiting the canonical IKKα/β/γ-NF-κB signaling and subsequent IFN production. Our findings thus unveil the innate immunosuppression by ORF9b, and provide insights into the host-virus interplay during the early stage of SARS-CoV-2 infection. Since the outbreak of severe acute respiratory syndrome (SARS) and Middle 25 East respiratory syndrome (MERS), coronaviruses (CoVs)-associated 26 diseases have emerged as a major threat to public health. COVID-19, a novel ORF9b may serve as an IFN antagonist. 148 We next examined whether ORF9b has an IFN antagonistic effect. 1E-1G and Figure S1D ). The IFN antagonistic activity of ORF9b was further 156 tested in HEK293T cells stimulated by either SARS-CoV-2 RNA or VSV RNA 157 ( Figure 1H and Figure S1E ). In addition, ORF9b suppressed the activation of SeV infection ( Figure 3E ). Nevertheless, the intracellular colocalization of GFP 204 and NEMO was not detected under viral stimulation ( Figure S3C ). Next, we sought to map the motif of ORF9b that is essential for its This study did not generate any unique datasets or code. Evidence of SARS-CoV-2 RNA in an Oropharyngeal (TRIM23) is critical in antiviral defense Ubiquitylation in innate and adaptive immunity Drives Development of COVID-19 Proteomics of SARS-CoV-2-infected host cells reveals therapy targets In Vitro Reconstitution of SARS-coronavirus mRNA Cap Methylation Control of Coronavirus Infection Through Plasmacytoid 710 Dendritic-Cell-Derived Type I Interferon Regulation of IRF-3-dependent innate immunity by the 717 papain-like protease domain of the severe acute respiratory syndrome coronavirus. The 718 IKKepsilon and TBK1 are essential components of 721 the IRF3 signaling pathway Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by 724 sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane Transmission of innate immune signaling by packaging 728 of cGAMP in viral particles Comparative host-coronavirus protein 731 interaction networks reveal pan-viral disease mechanisms A SARS-CoV-2 protein interaction map 734 reveals targets for drug repurposing Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 SARS-CoV-2 Cell Entry 740 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The 744 Lancet Mechanisms of MAVS Regulation at the Mitochondrial SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and 749 IgM responses SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70 SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG 755 and IgM responses Cytoplasmic Viral RNA Sensors: RIG-I-Like Receptors Jung, recognition of RNA viruses Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, 763 and nucleocapsid proteins function as interferon antagonists Activation and evasion of type I interferon responses by SARS-CoV-2 Parkin mediates nonclassical, 769 proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation MAVS 773 recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades Attenuation and Restoration of Severe Acute Respiratory 776 Syndrome Coronavirus Mutant Lacking 2'-o-methyltransferase Activity Type I and Type III Interferons -Induction, Signaling, Evasion, 779 and Application to Combat COVID-19 Dysregulation of immune response in patients with COVID-19 in Clinical infectious diseases : an official publication of the Infectious Diseases Society of Deciphering key features in protein structures with the new 789 ENDscript server IKK-gamma is an essential 791 regulatory subunit of the IkappaB kinase complex MyD88 Is Required for Protection From Lethal Infection With a Mouse-Adapted SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting 797 mitochondria and the MAVS/TRAF3/TRAF6 signalosome Upstream ORFs Prevent MAVS Spontaneous Aggregation and Regulate Innate Immune Immune suppression in the early stage of COVID-19 disease Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of 813 SARS Coronavirus Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus 816 (2019-nCoV) in vitro Virological assessment of hospitalized 819 patients with COVID-2019 Sensing of Lys 821 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation et 824 Recognition of SARS-CoV-2 by Full-Length Human ACE2 ORF 4b, and ORF 5 of Middle East 830 Respiratory Syndrome Coronavirus (MERS-CoV) Are Potent Interferon Antagonists SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent 834 interferon antagonists. Emerging microbes & infections 9 A pneumonia outbreak associated with a new coronavirus of probable bat origin A pneumonia outbreak associated with a new coronavirus of 840 probable bat origin A Novel Coronavirus from Patients with Pneumonia in China SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients